AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells

Cell Rep. 2023 May 30;42(5):112536. doi: 10.1016/j.celrep.2023.112536. Epub 2023 May 20.

Abstract

Here, we show that the tumor suppressor phosphatase and tensin homolog deleted from chromosome 10 (PTEN) sensitizes cells to ferroptosis, an iron-dependent form of cell death, by restraining the expression and activity of the cystine/glutamate antiporter system Xc- (xCT). Loss of PTEN activates AKT kinase to inhibit GSK3β, increasing NF-E2 p45-related factor 2 (NRF2) along with transcription of one of its known target genes encoding xCT. Elevated xCT in Pten-null mouse embryonic fibroblasts increases the flux of cystine transport and synthesis of glutathione, which enhances the steady-state levels of these metabolites. A pan-cancer analysis finds that loss of PTEN shows evidence of increased xCT, and PTEN-mutant cells are resistant to ferroptosis as a consequence of elevated xCT. These findings suggest that selection of PTEN mutation during tumor development may be due to its ability to confer resistance to ferroptosis in the setting of metabolic and oxidative stress that occurs during tumor initiation and progression.

Keywords: Akt; CP: Cancer; CP: Metabolism; GSK3β; NRF2; PTEN; cancer; cysteine; ferroptosis; glutathione; xCT.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cystine* / metabolism
  • Ferroptosis*
  • Fibroblasts / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Mice
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism

Substances

  • Cystine
  • Proto-Oncogene Proteins c-akt
  • NF-E2-Related Factor 2
  • Glycogen Synthase Kinase 3 beta